| Bivalirudin in patients with coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 20687895 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bivalirudin, a DTI, has evolved from relative obscurity as an anticoagulation option in patients resistant to or allergic to either LMWH or UFH to a commonly used, safe alternative. Most of the early studies comparing bivalirudin to UFH with or without a GP IIb/IIIa agent had composite endpoints (death, MI, bleeding) whose statistical significance were driven exclusively by a significant reduction in bleeding. Newer studies now demonstrate reductions in mortality, which has led to a paradigm shift in anticoagulant choice both in elective and emergent coronary procedures. We present the major studies that have brought bivalirudin to the forefront of coronary artery disease, specifically coronary interventional procedures. |
| | |
Authors:
|
Julie A Linden; George S Chrysant |
Related Documents
:
|
2307785 - The spectrum of diseases of small coronary arteries and their physiologic consequences. 2010445 - Occlusive arterial disease as a form of presentation of homocystinuria. 18291205 - Symptomatic coronary obstruction due to kawasaki disease in an adult. 14650385 - Stress myocardial perfusion imaging in the diagnosis and prognosis of women with suspec... 7483975 - Inferior vena cava thrombosis following percutaneous filter insertion: an unusual cause... 9240995 - Lower extremity arterial disease in sports. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cardiovascular & hematological agents in medicinal chemistry Volume: 8 ISSN: 1875-6182 ISO Abbreviation: Cardiovasc Hematol Agents Med Chem Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-06 Completed Date: 2011-02-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101266881 Medline TA: Cardiovasc Hematol Agents Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 199-203 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, INTEGRIS Baptist Medical Center, University of Oklahoma, Oklahoma City, Oklahoma 73112, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
therapeutic use* Clinical Trials as Topic Coronary Artery Disease / drug therapy* Hirudins Humans Peptide Fragments / therapeutic use* Recombinant Proteins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative analysis of stage specific gene regulation of apicomplexan parasites: Plasmodium falcipa...
Next Document: Amoxicillin-bearing microparticles: potential in the treatment of Listeria monocytogenes infection i...